Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
I am looking for
added new label for I am looking for
Advanced Filters
Found 56 clinical trials
Testing the Addition of an Anti-cancer Drug, BAY 1895344, With Radiation Therapy to the Usual Pembrolizumab Treatment for Recurrent Head and Neck Cancer

This phase I trial evaluates the best dose, possible benefits and/or side effects of combination therapy with elimusertib (BAY 1895344), stereotactic body radiation, and pembrolizumab in treating patients with head and neck squamous cell cancer that has come back (recurrent) and cannot be removed by surgery (unresectable). BAY 1895344 may …

  • 13 Jul, 2022
  • 1 location
Intratumoral Administration of Daromun in Non-melanoma Skin Cancer Patients (DUNCAN)

This clinical phase II study is designed to investigate the efficacy of intratumorally administered L19IL2/L19TNF in patients with injectable lesions of BCC or cSCC. Favorable tumor responses following intralesional treatment with L19IL2/L19TNF have been observed in patients with injectable melanoma lesions of stage III or IV, for injected and non-injected …

carcinoma of skin
skin cancer
melanoma skin
  • 01 May, 2022
  • 3 locations
Comparative Efficacy of Cemiplimab to Historical Standard of Care in France (TOSCA)

locally advanced cutaneous Squamous Cell Carcinoma (CSCC) who are not candidates for curative surgery or curative radiation, on overall survival (OS). Secondary Objectives: Assess

  • 10 Jun, 2022
  • 1 location
CemiplimAb Survivorship Epidemiology (CASE)

The objectives of the study are: To describe the effectiveness of cemiplimab 350 mg administered every 3 weeks (Q3W) for treatment of patients with advanced cutaneous squamous cell

exposure to radiation
  • 09 May, 2022
  • 44 locations
How Microbes and Metabolism May Predict Skin Cancer Immunotherapy Outcomes (MINING)

The purpose of this research study is to examine the relationship between the microbiota (microscopic organisms) in the gut and the activity of the immune system during skin cancer immunotherapy.

skin cancer
  • 31 Jan, 2022
  • 1 location
Clinical Benefit and Biomarker Analysis of Combination of PD-1/PD-L1 Immune Checkpoint Inhibitors and Radiotherapy

Inhibitors of the programmed cell death protein 1 (PD-1)/PD-L1 immune checkpoint signaling pathway are already approved in the treatment of various tumor entities in relapsed or metastatic stages. Different exploratory trials suggest that the combination of radiotherapy and PD-1/PD-L1 inhibitors is highly effective, especially in oligometastatic stages and if all …

programmed cell death protein 1
solid tumour
programmed cell death 1 ligand 1
  • 28 May, 2021
  • 1 location